Head-to-Head Comparison of Aptamer- and Antibody-Based Proteomic Platforms in Human Cerebrospinal Fluid Samples from a Real-World Memory Clinic Cohort.

High-throughput proteomic platforms are crucial to identify novel Alzheimer's disease (AD) biomarkers and pathways. In this study, we evaluated the reproducibility and reliability of aptamer-based (SomaScan 7k) and antibody-based (Olink Explore 3k) proteomic platforms in cerebrospinal fluid (CSF) samples from the Ace Alzheimer Center Barcelona real-world cohort. Intra- and inter-platform reproducibility were evaluated through correlations between two independent SomaScan assays analyzing the same samples, and between SomaScan and Olink results.

ChatGPT4's diagnostic accuracy in inpatient neurology: A retrospective cohort study.

Background: Large language models (LLMs) such as ChatGPT-4 (CG4) are proving to be valuable tools in the medical field, not only in facilitating administrative tasks, but in augmenting medical decision-making. LLMs have previously been tested for diagnostic accuracy with expert-generated questions and standardized test data. Among those studies, CG4 consistently outperformed alternative LLMs, including ChatGPT-3.

Evaluation of a Non-Enzymatic Electrochemical Sensor Based on Co(OH)-Functionalized Carbon Nanotubes for Glucose Detection.

This work reports on the assessment of a non-hydrolytic electrochemical sensor for glucose sensing that is developed using functionalized carbon nanotubes (fCNTs)/Co(OH). The morphology of the nanocomposite was investigated by scanning electron microscopy, which revealed that the CNTs interacted with Co(OH). This content formed a nanocomposite that improved the electrochemical characterizations of the electrode, including the electrochemical active surface area and capacitance, thus improving sensitivity to glucose.

Associations of plasma SMOC1 and soluble IL6RA levels with the progression from mild cognitive impairment to dementia.

Despite the central role attributed to neuroinflammation in the etiology and pathobiology of Alzheimer's disease (AD), the direct link between levels of inflammatory mediators in blood and cerebrospinal fluid (CSF) compartments, as well as their potential implications for AD diagnosis and progression, remains inconclusive. Moreover, there is debate on whether inflammation has a protective or detrimental effect on disease onset and progression. Indeed, distinct immunological mechanisms may govern protective and damaging effects at early and late stages, respectively.